Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication

References

• International Diabetes Federation2009IDF Diabetes Atlas Available from: http://www.diabetesatlas.org/content/regional-overview. Accessed 2010 May 26.
   Google Scholar
• Centers for Disease Control and PreventionNational diabetes fact sheet: General information and national estimates on diabetes in the United States2007 Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed 2010 May 26.
   Google Scholar
• StephensJMBottemanMFHayJWEconomic impact of antidiabetic medications and glycemic control on managed care organizations: A review of the literatureJ Manag Care Pharm200612213014216515371
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of Medical Care in Diabetes – 2010Diabetes Care2010Suppl 1S11S6120042772
   PubMed Web of Science ®Google Scholar
• InzucchiSEOral antihyperglycemic therapy for type 2 diabetes: Scientific reviewJAMA2002287336037211790216
   PubMed Web of Science ®Google Scholar
• JoySVClinical pearls and strategies to optimize patient outcomesDiabetes Educ200834Suppl 354S59S18525065
   PubMed Web of Science ®Google Scholar
• BruntonSBeyond glycemic control: Treating the entire type 2 diabetes disorderPostgrad Med20091215688119820276
   PubMed Web of Science ®Google Scholar
• PollackMFPurayidathilFWBolgeSCWilliamsSAPatient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of lifeDiabetes Res Clin Pract201087220421020036433
   PubMed Web of Science ®Google Scholar
• MarrettEStargardtTMavrosPAlexanderCMPatient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: Associations with hypoglycaemia and weight gainDiabetes Obes Metab200911121138114419758360
   PubMed Web of Science ®Google Scholar
• BarronJWahlPFisherMPlauschinatCEffect of prescription copayments on adherence and treatment failure with oral antidiabetic medicationsP T200833953255319750032
   PubMedGoogle Scholar
• YeawJBennerJSWaltJGSianSSmithDBComparing adherence and persistence across 6 chronic medication classesJ Manag Care Pharm200915972874019954264
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic controlEndocr Pract200915654055919858063
   PubMed Web of Science ®Google Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysisJAMA2007298219420617622601
   PubMed Web of Science ®Google Scholar
• ZarowitzBJConnerCThe intersection of safety and adherence: New incretin-based therapies in patients with type 2 diabetes mellitusPharmacotherapy20092912 Pt 255S67S19947817
   PubMed Web of Science ®Google Scholar
• KhanHCoyleFMChowdhuryTAPatients’ preference for subsequent therapy following secondary failure of metformin and sulphonylureaPract Diabetes Int2009267282284
   Google Scholar
• HayesRPBowmanLMonahanPOMarreroDGMcHorneyCAUnderstanding diabetes medications from the perspective of patients with type 2 diabetes: Prerequisite to medication concordanceDiabetes Educ200632340441416772656
   PubMed Web of Science ®Google Scholar
• CookeCELeeHYTongYPHainesSTPersistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organizationCurr Med Res Opin201026123123819921965
   PubMed Web of Science ®Google Scholar
• PratleyRENauckMABaileyTLiraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trialLancet201037597241447145620417856
   PubMed Web of Science ®Google Scholar
• FineJTColditzGACoakleyEHA prospective study of weight change and health-related quality of life in womenJAMA1999282222136214210591335
   PubMed Web of Science ®Google Scholar
• TiessenRGCastaigneJPDreyfusJFNemanskyMKruizingaHHvan VlietAAPharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjectsInt J Clin Pharmacol Ther200846944345218793574
   PubMed Web of Science ®Google Scholar
• BolgeSCDoanJFKannanHBaranRWAssociation of insomnia with quality of life, work productivity, and activity impairmentQual Life Res200918441542219288223
   PubMed Web of Science ®Google Scholar
• NauckMAMeiningerGShengDTerranellaLSteinPPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trialDiabetes Obes Metab20079219420517300595
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetesDiabetes Care2009321849018931095
   PubMed Web of Science ®Google Scholar
• NathanDMKuenenJBorgRTranslating the A1C assay into estimated average glucose valuesDiabetes Care20083181473147818540046
   PubMed Web of Science ®Google Scholar
• JendleJTorffvitORidderstråleMWillingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetesCurr Med Res Opin201026491792320163195
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceNICE appraisal of liraglutide for type 2 diabetes mellitus Available from: http://www.nice.org.uk/media/C2F/63/2010015Type2DiabetesLiraglutide.pdf. Accessed 2010 May 26.
   Google Scholar
• Williams-HermanDEngelSSRoundESafety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetesBMC Endocr Disord201010720412573
   PubMed Web of Science ®Google Scholar